Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer.

MLA

Reizine, Natalie, et al. “Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer.” JCO Precision Oncology, vol. 7, Mar. 2023, p. e2200483. EBSCOhost, https://doi.org/10.1200/PO.22.00483.

APA

Reizine, N., Socco, S., Weng, E., Atueyi, U., Mehta, V., & Patnaik, A. (2023). Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. JCO Precision Oncology, 7, e2200483. https://doi.org/10.1200/PO.22.00483

Chicago

Reizine, Natalie, Samantha Socco, Eric Weng, Uka Atueyi, Vikas Mehta, and Akash Patnaik. 2023. “Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer.” JCO Precision Oncology 7 (March): e2200483. doi:10.1200/PO.22.00483.